Allarity Therapeutics (ALLR) Expected to Announce Quarterly Earnings on Monday

Allarity Therapeutics (NASDAQ:ALLR) is expected to be releasing its results before the market opens on Monday, March 30th. Analysts expect Allarity Therapeutics to post earnings of ($0.22) per share for the quarter.

Allarity Therapeutics Price Performance

ALLR stock opened at $1.07 on Friday. The company’s 50-day moving average is $1.05 and its 200-day moving average is $1.22. The stock has a market capitalization of $17.21 million, a PE ratio of -1.81 and a beta of 0.20. Allarity Therapeutics has a 1 year low of $0.61 and a 1 year high of $2.35.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in Allarity Therapeutics in the second quarter valued at $27,000. XTX Topco Ltd purchased a new stake in shares of Allarity Therapeutics in the 4th quarter worth approximately $36,000. Geode Capital Management LLC grew its stake in shares of Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after acquiring an additional 16,729 shares during the last quarter. DRW Securities LLC purchased a new stake in Allarity Therapeutics during the 4th quarter valued at about $133,000. Finally, Citadel Advisors LLC bought a new stake in shares of Allarity Therapeutics during the third quarter valued at approximately $149,000. Institutional investors own 11.53% of the company’s stock.

Analysts Set New Price Targets

ALLR has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets lifted their price objective on Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Allarity Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.